scispace - formally typeset
R

Rakesh K. Jain

Researcher at Harvard University

Publications -  1528
Citations -  198912

Rakesh K. Jain is an academic researcher from Harvard University. The author has contributed to research in topics: Angiogenesis & Cancer. The author has an hindex of 200, co-authored 1467 publications receiving 177727 citations. Previous affiliations of Rakesh K. Jain include Government Medical College, Thiruvananthapuram & University of Oslo.

Papers
More filters
Journal ArticleDOI

Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells.

TL;DR: Comparison of in vitro vs in vivo results suggests an over-riding role of host stromal cells in extracellular matrix production subjected to modulation by tumour cells, which might mean that caution must be exercised in extrapolating drug penetrability from spheroids and multilayer cellular sandwiches consisting of only tumours to tumours in vivo.
Journal ArticleDOI

Analysis of cell flux in the parallel plate flow chamber: implications for cell capture studies.

TL;DR: The development and validation of a mathematical model based on the sedimentation rate and velocity profile in the chamber for the delivery of cells from a flowing suspension to the chamber surface and results show that the flux depends on the bulk cell concentration, the distance from the entrance point, and the flow rate of the cell-containing medium.
Journal ArticleDOI

Return of lymphatic function after flap transfer for acute lymphedema.

TL;DR: Acute lymphedema developing after ligation of tail lymphatics in mice can be prevented by myocutaneous flap transfer and restored lymphatic continuity and function were demonstrable using lymphoscintigraphy and fluorescence microlymphangiography.
Journal ArticleDOI

Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies

TL;DR: How reprogramming various facets of the TME (blood vessels, myeloid cells, and regulatory T cells [Tregs]) may overcome TME-instigated resistance mechanisms to immunotherapy is discussed.